Abbott Laboratories has received clearance from the U.S. Food and Drug Administration (FDA) for its Ellipse implantable cardioverter defibrillator (ICD) with MRI-conditional labeling.
Patients implanted with an Ellipse ICD may now undergo MRI scans, the company said. The clearance follows the approval of Abbott's Assurity MRI pacemaker earlier this year.
